Ligand Pharmaceuticals Inc. Announces Positive Preclinical Data On Small-Molecule G-CSF Receptor Agonist At The 55th Annual Meeting Of The American Society of Hematology
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that data from preclinical studies on its granulocyte colony stimulating factor (G-CSF) receptor agonist program were featured in a poster presentation today at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans.
Help employers find you! Check out all the jobs and post your resume.